Fresenius Kabi Oncology Limited(BSE:532545 NSE:FKONCO) ,Company Snapshot, Recent Developments, Latest News, Financials, Price Charts, Ratios, Contact Information

Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals

Home

News Centre

IPO

Markets	Companies	Research	Industries	E-Mail Page

my Last 5 Scrips
Company	BSE Price(Rs)	% Chg
Tata Mot	288.30	1.18
I T C Lt	322.85	2.20
Tata Stl	272.40	6.25
Hindalco	97.70	6.24
Jindal S	222.15	9.62
Clear All	Clear Last

NSE Live
Nifty Live Prices Live Quotes Top Gainers/Losers Top 10 Turnover No Delivery Stocks

BSE Live
BSE30 Live Prices Live Quotes Top Gainers/Losers Top 10 Turnover No Delivery Stocks

Market Pulse
Leaders Laggards FII Activity Mutual Fund Activity Meetings

Results Watch
Results Calendar Results Announced

IPO Watch

Company
Snapshots Quotes Charts Financials Recent News Broker Research Meetings Research Tutorial Discussion Forum

Research
Research Reports

Sector Watch

Economy Watch

Snapshot-Fresenius Kabi Oncology Limited

Fresenius Kabi Oncology Limited

Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:532545	NSE:FKONCO	Bloomberg:FKOL@IN	Reuters:FRES.BO
Market Lot: 1	Face Value: 1	ISIN Demat: INE575G01010

Quotes	Snapshot	Charts	Financials	Research	Recent News
Peer Group	AGM/AM	MF Holding	Discussion Forum	BSE/NSE Notices	BSE/NSE Deals

Recent Developments
27-MAY-11 Fresenius Kabi Oncology today announced that the company to further leverage its R&D and manufacturing competencies by entering into contract R&D and manufacturing agreements with Fresenius Kabi Germany and its affiliates for future products without affecting existing product business and intellectual property rights (IPRs). 05-APR-10 Fresenius Kabi Oncology announced that it has entered into a license and settlement agreement with S... More..
Business Profile	Future Plans

One To One

Latest News

Fresenius Kabi Oncology earnings plunges 53.16% for Dec`10 qtr -IRIS 01-Feb-11

Brief Financials (in Rs. Mn.)

Period ending (months)	30-Jun-2012(3)	31-Mar-2012 (12)	31-Mar-2011 (12)
Net sales	1240.65	4711.19	4033.82
Other Income	4.79	13.86	62.86
Total Income	1245.43	4725.05	4096.68
Cost of goods sold	1111.60	4568.61	3163.93
OPBDIT	133.84	156.44	932.75
PAT	130.36	509.51	492.42
Gross Block	-	-	-
Equity capital	158.23	158.23	158.23
EPS (Rs.)	-	3.22	3.11
DPS (Rs.)	-	-	-
BV (Rs.)	-	-	-
P/E range (x)	-	25.36 - 51.24	26.46 - 62.30
Debt / Equity (x)	-	-	-
Operating margin (% of OI)	10.7	3.3	22.8
Net margin (% of OI)	10.5	10.8	12.0